Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Common Equity: 2019-2024

Historic Common Equity for Beam Therapeutics (BEAM) over the last 6 years, with Dec 2024 value amounting to $733.5 million.

  • Beam Therapeutics' Common Equity rose 22.08% to $966.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $966.0 million, marking a year-over-year increase of 22.08%. This contributed to the annual value of $733.5 million for FY2024, which is 25.25% down from last year.
  • According to the latest figures from FY2024, Beam Therapeutics' Common Equity is $733.5 million, which was down 25.25% from $981.3 million recorded in FY2023.
  • Beam Therapeutics' Common Equity's 5-year high stood at $981.3 million during FY2023, with a 5-year trough of $245.6 million in FY2020.
  • In the last 3 years, Beam Therapeutics' Common Equity had a median value of $733.5 million in 2024 and averaged $816.1 million.
  • In the last 5 years, Beam Therapeutics' Common Equity skyrocketed by 236.67% in 2021 and then decreased by 25.25% in 2024.
  • Beam Therapeutics' Common Equity (Yearly) stood at $245.6 million in 2020, then skyrocketed by 236.67% to $826.7 million in 2021, then declined by 11.28% to $733.5 million in 2022, then skyrocketed by 33.79% to $981.3 million in 2023, then declined by 25.25% to $733.5 million in 2024.